Esperion Therapeutics (ESPR) Tops Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts ESPR Hot Sheet
Join SI Premium – FREE
Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $69.11 million versus the consensus estimate of $63.45 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
